<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02398318</url>
  </required_header>
  <id_info>
    <org_study_id>RCT-YY2015-CRODS</org_study_id>
    <nct_id>NCT02398318</nct_id>
  </id_info>
  <brief_title>China Refractory Obsessive-Compulsive Disorder Deep Brain Stimulation Study</brief_title>
  <acronym>CRODS</acronym>
  <official_title>China Refractory-Obsessive Compulsive Disorder Deep Brain Stimulation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Suzhou Sceneray Medical Co. , Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Refractory obsessive-compulsive disorder (OCD) is a disabling condition. Deep brain
      stimulation (DBS) of the nucleus accumbens is the most tested therapeutic avenue for
      refractory OCD. However, large scale randomized controlled trials to evaluate the
      effectiveness of this approach are rare.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    A pilot study is recruiting
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score</measure>
    <time_frame>Baseline (preoperative), 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Obsessive-Compulsive Inventory - Revised (OCI-R) Score</measure>
    <time_frame>Baseline (preoperative), 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Anxiety Scale, Hamilton Depression Scale-17, Beck Anxiety Scale, Beck Depression Scale-1 Score</measure>
    <time_frame>Baseline (preoperative), 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Temperament and Character Inventory revised version (TCI-R) Score</measure>
    <time_frame>Baseline (preoperative), 6 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iowa Gambling Task (change in task performance scores)</measure>
    <time_frame>Baseline (preoperative), 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional magnetic resonance imaging (fMRI) images</measure>
    <time_frame>Baseline (preoperative), 2 weeks after last ERP session (average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in positron emission tomography (PET) brain glucose metabolism images</measure>
    <time_frame>Baseline (preoperative), 6 months after surgery</time_frame>
    <description>Fluoro-D-glucose (FDG) will be utilized to evaluate cerebral metabolism at Baseline (preoperative) and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: Global assessment of function</measure>
    <time_frame>Baseline (preoperative), 2 weeks after last ERP session (average), 6 months after surgery, 24 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability: WHO disability assessment 2.0</measure>
    <time_frame>Baseline (preoperative), 2 weeks after last ERP session (average), 6 months after surgery, 24 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model Task (change in task performance scores)</measure>
    <time_frame>Baseline (preoperative), 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Bilateral Nucleus Accumbens DBS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 month period of active bilateral nucleus accumbens DBS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Bilateral Nucleus Accumbens DBS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>6 month period of sham bilateral nucleus accumbens DBS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)</intervention_name>
    <description>High frequency stimulation applied using Suzhou Sceneray® DBS hardware (1120 electrode, 1180 (S) battery).</description>
    <arm_group_label>Bilateral Nucleus Accumbens DBS</arm_group_label>
    <other_name>Active DBS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Bilateral Nucleus Accumbens DBS</intervention_name>
    <description>DBS system switched off.</description>
    <arm_group_label>Sham Bilateral Nucleus Accumbens DBS</arm_group_label>
    <other_name>Sham DBS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 60 years.

          2. A primary diagnosis of OCD, defined according to the criteria of the Diagnostic and
             Statistical Manual of Mental Disorders, fourth edition (DSM-IV).

          3. Chronic: disease duration of more than 5 years.

          4. Severity: a score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) of more than
             25 or one subscale score of more than 15 ; a score for severity of illness on the
             Clinical Global Impression (CGI) scale of more than 4.

          5. Disability: a score on the Global Assessment Functioning (GAF) scale of less than 45.

          6. Refractory: a lack of response to drug therapy after adequate administration (defined
             as more than 12 weeks at the maximum tolerated dose) of at least three
             serotonin-reuptake inhibitors, one of which had to be clomipramine. Adequate behavior
             therapy, defined as 20 sessions of exposure and response prevention (ERP) with a
             therapist who has substantial expertise in OCD treatment.

        Exclusion Criteria:

          1. Schizophrenic disorder; bipolar disorder; substance abuse or dependence (except for
             dependence on nicotine), as assessed with the use of the Mini-International
             Neuropsychiatric Interview (MINI 6.0.0).

          2. Cluster A or B personality disorder according to DSM-IV criteria, as assessed with the
             use of the Structured Clinical Interview II.

          3. A current severe major depressive episode, determined according to DSM-IV criteria (as
             assessed with the use of the MINI 6.0.0) and defined by the Hamilton Depression Rating
             Scale-17 (HAMD) score of more than 20 and a risk of suicide.

          4. Abnormal cognitive status (measured by MoCA), abnormal findings on functional magnetic
             resonance imaging (MRI) of the brain; and no contraindications to surgery or
             anesthesia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bomin Sun, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangzhou psychiatric hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510370</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zuo C, Ma Y, Sun B, Peng S, Zhang H, Eidelberg D, Guan Y. Metabolic imaging of bilateral anterior capsulotomy in refractory obsessive compulsive disorder: an FDG PET study. J Cereb Blood Flow Metab. 2013 Jun;33(6):880-7. doi: 10.1038/jcbfm.2013.23. Epub 2013 Feb 27.</citation>
    <PMID>23443174</PMID>
  </reference>
  <reference>
    <citation>Wu H, Van Dyck-Lippens PJ, Santegoeds R, van Kuyck K, Gabriëls L, Lin G, Pan G, Li Y, Li D, Zhan S, Sun B, Nuttin B. Deep-brain stimulation for anorexia nervosa. World Neurosurg. 2013 Sep-Oct;80(3-4):S29.e1-10. doi: 10.1016/j.wneu.2012.06.039. Epub 2012 Jun 25. Review.</citation>
    <PMID>22743198</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <last_update_submitted>December 4, 2016</last_update_submitted>
  <last_update_submitted_qc>December 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Bomin Sun</investigator_full_name>
    <investigator_title>Director of functional neurosurgery department</investigator_title>
  </responsible_party>
  <keyword>neurosurgery</keyword>
  <keyword>deep brain stimulation</keyword>
  <keyword>exposure response prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

